Magnolia Bark Supplement Manufacturer

Magnolia bark is the botanical. Honokiol is one assayed compound in that bark; magnolol is the isomer usually run on the same HPLC. You are buying one of: bark identity, extract milligrams × a named %, or honokiol milligrams as the hero. Those are not the same purchase order.

Under the applicable pharmacopoeial monograph, European Pharmacopoeia defines Magnoliae officinalis cortex as dried stem and branch bark of M. officinalis and requires a minimum combined magnolol + honokiol of 2.0%, calculated with reference to the dried drug (reported for Ph. Eur. 8.1; the same combined floor is cited for Ph. Eur. 11).[1] The Chinese Pharmacopoeia has used the same combined 2.0% floor on dried houpo cortex (reported for the 2010 English edition).[2] Confirm the edition that applies to the destination market. That floor is a crude-drug quality criterion. It is not a commercial extract labeled “2% honokiol,” and it is not a finished-capsule guarantee. Other pharmacopoeial systems use different limits; do not treat 2.0% as a worldwide default grade.

Incoming assay ≠ finished-product assay. 2% honokiol ≠ 2% combined honokiol + magnolol. Write the PO as honokiol x% HPLC, magnolol x% HPLC, a named sum, or both peaks plus the sum.

Illustration only—not an intake: 200 mg extract × 2% honokiol = 4 mg honokiol if the % is honokiol and finished assay agrees. 40 mg × 90% = 36 mg. Artwork, COA, and fill change together.

Commercial dietary-supplement labels and measured honokiol/magnolol can disagree; method, assay basis, and finished-unit testing are the specification, not a supplier’s unnamed “2%.”[3]

Extract weight × assay = theoretical marker amount. This calculation does not establish a recommended intake or a finished-product assay.

Not sure which specification matches your product? Send Your Magnolia Bark Specification / COA. Include the current COA, target honokiol or magnolol level, and serving size. We check whether the quoted material and assay basis match.

Generic literacy: How to Read a COA.

Illustration only—not a released lot. Incoming extract: M. officinalis bark; honokiol 2.1% HPLC; magnolol 1.8%; sum 3.9%. That file does not prove 4.2 mg honokiol in a 200 mg finished capsule.

Send two COAs. We compare whether they are quoting the same species, plant part, analyte, and milligram basis.

Changing the extract supplier after approval restarts qualification. Two drums blended to “hit 2%” are not one approved SKU.

Path: Incoming identity (M. officinalis bark) → HPLC as specified → controlled blend → capsule, tablet, powder, or gummy fill → metal detection / pack inspection → finished tests as scoped → batch release.

When a milligram is declared on the finished label, scope finished-unit assay. Incoming drum % × fill weight is not that number.

Packaging and stability should be evaluated against the actual commercial pack and storage conditions, particularly when a finished product declares honokiol or magnolol. Dating should be based on the packaged SKU rather than an unpackaged blend. Storage can change measured honokiol/magnolol; do not assume a single degradation curve.[4]

Methods: quality control. Scale-up: manufacturing capacity.

Indicative commercial starting points — final MOQ and lead time depend on formula, dosage form, packaging, testing, and production schedule.

Flavor work, dual HPLC, Relora-type trademark review, and finished honokiol assay add time before the sample clock starts.

OEM — you send a BOM. ODM — you send channel, format, and a milligram direction.

Qualitative manufacturing review, not a dosing or drug-interaction table.

Gastrointestinal discomfort and next-day drowsiness are common warning-review items.

Regulatory note: U.S. structure/function claims are subject to 21 CFR 101.93 and applicable FDA requirements. Destination-market review is required before artwork approval; manufacturing documentation is not legal or regulatory clearance.